Guidance in brief: Prevention and control of blood-borne viruses in prison settings
This guidance is intended for policymakers responsible for the planning and delivery of healthcare services in the national or sub-national custodial system and all professionals responsible for the health and well-being of people in prison, including community-based service providers and those facilitating continuity of care in the community.
World Hepatitis Day 2018
28 Jul 2018 to 28 Jul 2018 - On the occasion of World Hepatitis Day, ECDC launched online prevalence database for hepatitis B and C which included data mainly based on peer-reviewed cross sectional studies from 2006 onwards.
Public health guidance on active case finding of communicable diseases in prison settings
23 May 2018 - This joint guidance from ECDC and the European Monitoring Centre for Drugs and Drug Addiction provides EU/EEA Member States with evidence-based scientific advice on active case finding options. These options can be applied to the planning and implementation of interventions that promote the early diagnosis of communicable diseases in prison settings.
Systematic review on active case finding of communicable diseases in prison settings
23 Nov 2017 - The objective of this report is to systematically review the evidence on active case finding in prison settings, with a focus on the European Union (EU) and the European Economic Area (EEA) region.
Systematic review on the diagnosis, treatment, care and prevention of tuberculosis in prison settings
30 May 2017 - The objective of this report is to systematically review data on the diagnosis, treatment, care and prevention of tuberculosis in prison settings, with a focus on the countries of the European Union and the European Economic Area.
Cost-effectiveness analysis of programmatic screening strategies for latent tuberculosis infection in the EU/EEA
23 Mar 2018 - The elimination of tuberculosis (TB) in Europe will require the management of latent tuberculosis infection (LTBI) in key populations. Management of LTBI requires the identification and adequate treatment of infected people. It is currently unknown how screening and treatment of key populations should be best organised to have the highest impact with the available resources.